Business Context and Reporting Period
Company: USANA Health Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter ended April 2, 2005
Business Overview: USANA develops, manufactures, and distributes nutritional and personal care products through a network marketing system using independent "Associates" and direct sales to "Preferred Customers." The company operates two segments: Direct Selling (primary business) and Contract Manufacturing.
Key Financial Metrics
| Metric | Q1 2005 (Actual) | Q1 2004 (Prior Year) |
|---|---|---|
| Net Sales | $76.6 million | $61.8 million |
| Gross Profit | $58.6 million (76.5% margin) | $46.7 million (75.6% margin) |
| Operating Income | $13.6 million | $9.3 million |
| Net Earnings | $8.9 million | $6.2 million |
| Diluted EPS | $0.45 | $0.30 |
| Cash and Equivalents | $22.0 million | $14.9 million (end of Q1 2004) |
| Operating Cash Flow | $7.5 million | $7.8 million |
| Debt | $0 (No outstanding debt) | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 24.0% year-over-year, driven by a 24.0% increase in active Associates and a 20.0% increase in active Preferred Customers. Strong growth was noted in Mexico and Singapore.
- Profitability: Net earnings rose 43.7% to $8.9 million. Gross profit margin improved to 76.5% from 75.6%, aided by a favorable product mix and lower costs on acquired inventory.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales to 19.4% from 21.5%, reflecting operating leverage. Associate incentives increased slightly to 39.6% of segment sales due to higher payout rates.
- Liquidity: Cash and cash equivalents increased by $7.0 million to $22.0 million. Working capital improved from $18.1 million to $29.6 million.
- Segment Performance: The Direct Selling segment contributed the majority of growth. The Contract Manufacturing segment saw sales increase by 25.7% and achieved a gross profit margin of 7.1% compared to zero in the prior year.
Guidance, Outlook, and Risks
Guidance and Outlook
- Q2 2005 Sales: Expected consolidated net sales in the range of $78 million to $80 million.
- Fiscal 2005 Sales: Expected consolidated net sales in the range of $319 million to $327 million.
- Tax Rate: Effective tax rate expected to be 35.0% for the full year 2005, up from 34.0% in 2004, due to the American Jobs Creation Act.
- Share Repurchases: Subsequent to the quarter, the Board authorized an additional $30 million for share repurchases. The company repurchased 235 shares for approximately $10 million between April 2 and April 29, 2005.
Risks and Contingencies
- Raw Materials: Persistent shortage and higher prices for Coenzyme Q10 (CoQ10) may pressure gross margins, though multiple sources have been qualified.
- Foreign Currency: Approximately 56.8% of sales are outside the U.S. A strengthening U.S. dollar negatively impacts reported sales and earnings. No hedging contracts were in place as of the report date.
- Network Marketing Risks: Dependence on Associates, high turnover, and regulatory scrutiny of network marketing practices.
- Key Personnel: Reliance on Founder and CEO Myron W. Wentz, Ph.D.
Investor Verification Checklist
- Associate Growth Sustainability: Verify if the 24% growth in active Associates is sustainable or driven by temporary promotions.
- CoQ10 Supply Chain: Confirm the company's ability to secure CoQ10 at stable prices to protect gross margins.
- Share Repurchase Impact: Assess the impact of the recent $30 million authorization and subsequent $10 million buyback on future liquidity and capital allocation.
- Foreign Currency Exposure: Monitor exchange rate fluctuations, particularly for the Canadian, Australian, and New Taiwan dollars, given the lack of active hedging contracts.
- Contract Manufacturing Viability: Evaluate the long-term profitability of the Contract Manufacturing segment, which relies on a limited number of customers (four customers accounted for >10% of segment sales each).